<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653456</url>
  </required_header>
  <id_info>
    <org_study_id>RMS-102</org_study_id>
    <nct_id>NCT02653456</nct_id>
  </id_info>
  <brief_title>Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease</brief_title>
  <official_title>A Prospective, Multi Center Pilot Study Evaluating Plaque Photoablation Using the RA-308 Excimer Laser in Subjects With Symptomatic Infrainguinal Lower Extremity Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ra Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ra Medical Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of an excimer laser in the
      treatment of patients with lower extremity vascular disease with chronic total occlusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi center, prospective, non-randomized, open-label study conducted at a
      minimum of one investigational center. 50 subjects can be enrolled. Follow-up occurs at the
      end of the procedure in the form of an angiogram to determine if the lesion was crossed.
      Additional follow-up may not necessary because of the binary nature of the crossing, and also
      because any future follow-up would be assessing the effectiveness of adjunct therapy, e.g.
      balloon angioplasty. Long term results are entirely dependent on this subsequent treatment.
      Because the DABRA crosser only allows adjunct devices to be used, 30-day follow-up measuring
      the performance of the adjunct therapy might affect the physician's choice of therapy, and
      compromise the patient's treatment. Therefore, 30-day follow-up, which evaluates the
      effectiveness of the adjunct therapy, might raise ethical concerns. However, the follow-up
      can be done by Ankle-Brachial Index, Doppler ultrasound, auscultation, or by discussion of
      the level of claudication and motion pain with the patient. To evaluate the safety and
      efficacy of the RA-308 Excimer Laser System and DABRA Catheter for treating subjects with
      symptomatic infrainguinal lower extremity vascular disease with chronic total occlusions that
      cannot be crossed with standard guide wires, or lesions where an attempt to cross would, in
      the opinion of the interventionalist, result in either a subintimal path or a perforation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2016</start_date>
  <completion_date type="Actual">July 14, 2017</completion_date>
  <primary_completion_date type="Actual">May 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crossing the Target Lesion</measure>
    <time_frame>at time of procedure</time_frame>
    <description>Crossing the target lesion based on angiographic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no Device-related Major Adverse Events</measure>
    <time_frame>at time of procedure, up to an hour</time_frame>
    <description>Number of participants with no device-related major adverse events as determined by physician evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with target lesion revascularization as determined by physician evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with target lesion revascularization as determined by physician evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>RA-308 Excimer Laser and DABRA Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RA-308 Excimer Laser and DABRA Catheter</intervention_name>
    <description>See information already included in arm description</description>
    <arm_group_label>RA-308 Excimer Laser and DABRA Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  symptomatic infrainguinal lower extremity vascular disease (Rutherford category 3, 4,
             5 or 6), stable for at least 2 weeks prior to study inclusion

          -  lesions in the superficial femoral artery (SFA), popliteal, or infrapopliteal arteries
             at least one angiographically identifiable infrageniculate artery

          -  patients must be poor surgical candidates, indicated by at least one of the following
             conditions:

          -  absence of venous autologous grafts (that is, lack of a suitable vein to use for
             bypass)

          -  poor (diffusely diseased or &lt;=1mm diameter) or no distal vessels available for graft
             anastamosis

          -  high risk of surgical mortality, evidenced by American Society of Anesthesiologists
             Physical Class 4 or higher

        Exclusion Criteria:

          -  age below 18 years

          -  pregnancy, or plan to become pregnant

          -  participation in another cardiovascular or peripheral vascular study

          -  myocardial infarction (MI) in prior month

          -  stents at treatment site

          -  disorders or allergies precluding use of radiographic contrast

          -  renal insufficiency sever enough to contraindicate use of radiographic contrast

          -  contraindication to treatment with anticoagulants

          -  untreated ipsilateral iliac stenosis &gt;70%

          -  inability or unwillingness of the patient to comply with intended examinations

          -  unavailability of required procedural or imaging equipment

          -  lesion located in a graft

          -  hemodynamically significant arrhythmia or left ventricular ejection fraction &lt;20%

          -  life expectancy less than 6 months

          -  necrosis necessitating major amputation

          -  unwillingness of the patient to be anti-coagulated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehtisham Mahmud</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Heart &amp; Vascular Clinic</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merit Health Wesley</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <results_first_submitted>August 27, 2018</results_first_submitted>
  <results_first_submitted_qc>September 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2018</results_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>excimer laser</keyword>
  <keyword>percutaneous catheter</keyword>
  <keyword>photoablation</keyword>
  <keyword>chronic total occlusion</keyword>
  <keyword>symptomatic infrainguinal lower extremity vascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02653456/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RA-308 Excimer Laser and DABRA Catheter</title>
          <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>subjects have a chronic total occlusion in the infrainguinal lower extremities</population>
      <group_list>
        <group group_id="B1">
          <title>RA-308 Excimer Laser and DABRA Catheter</title>
          <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease. The catheter and laser are a system, and cannot be used separately.
RA-308 Excimer Laser and DABRA Catheter: See information already included in arm description</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="47" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic total occlusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Crossing the Target Lesion</title>
        <description>Crossing the target lesion based on angiographic analysis</description>
        <time_frame>at time of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RA-308 Excimer Laser and DABRA Catheter</title>
            <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease. The catheter and laser are a system, and cannot be used separately.
RA-308 Excimer Laser and DABRA Catheter: See information already included in arm description</description>
          </group>
        </group_list>
        <measure>
          <title>Crossing the Target Lesion</title>
          <description>Crossing the target lesion based on angiographic analysis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no Device-related Major Adverse Events</title>
        <description>Number of participants with no device-related major adverse events as determined by physician evaluation</description>
        <time_frame>at time of procedure, up to an hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RA-308 Excimer Laser and DABRA Catheter</title>
            <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease. The catheter and laser are a system, and cannot be used separately.
RA-308 Excimer Laser and DABRA Catheter: See information already included in arm description</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Device-related Major Adverse Events</title>
          <description>Number of participants with no device-related major adverse events as determined by physician evaluation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Number of participants with target lesion revascularization as determined by physician evaluation</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RA-308 Excimer Laser and DABRA Catheter</title>
            <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
RA-308 Excimer Laser and DABRA Catheter: See information already included in arm description</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Number of participants with target lesion revascularization as determined by physician evaluation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Number of participants with target lesion revascularization as determined by physician evaluation</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RA-308 Excimer Laser and DABRA Catheter</title>
            <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease. The catheter and laser are a system, and cannot be used separately.
RA-308 Excimer Laser and DABRA Catheter: See information already included in arm description</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Number of participants with target lesion revascularization as determined by physician evaluation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event data was collected from the time of the procedure up to 6 months post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RA-308 Excimer Laser and DABRA Catheter</title>
          <description>Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease. The catheter and laser are a system, and cannot be used separately.
RA-308 Excimer Laser and DABRA Catheter: See information already included in arm description</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President of Regulatory Affairs and Quality Assurance</name_or_title>
      <organization>Ra Medical Systems, Inc.</organization>
      <phone>877-635-1800 ext 207</phone>
      <email>vchester@ramed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

